We have observed
10 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after December 01, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
HETEROLOGOUS PRIME-BOOST IMMUNIZATION USING MEASLES VIRUS-BASED VACCINES
BATCHES OF RECOMBINANT ADENOVIRUS WITH ALTERED TERMINAL ENDS
HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING HEPATITIS B VIRUSES AND USES THEREOF
PNEUMATIC ALTERNATING PRESSURE MEMBRANE CELL SEPARATION SYSTEM
IMPROVED ADENOVIRUS FORMULATIONS
METHOD FOR THE CLARIFICATION OF HIGH DENSITY CRUDE CELL CULTURE HARVEST
REPLICATING RECOMBINANT ADENOVIRUS VECTORS, COMPOSITIONS, AND METHODS OF USE THEREOF
ASSAYS FOR RECOMBINANT EXPRESSION SYSTEMS
RECOMBINANT ADENOVIRUS EXPRESSING TWO TRANSGENES WITH A BIDIRECTIONAL PROMOTER
METHODS FOR PREVENTING PLASTIC-INDUCED DEGRADATION OF BIOLOGICALS